The Netherlands' Forbion Capital Partners has wrapped up the first close in a planned third fund, raking in $120 million with plans to stake a new generation of biotechs. Forbion expects to raise as much as $250 million for its new fund, enough to support 12 to 15 investments in therapeutics, devices and diagnostics. Among the group's recent exits are Santaris Pharma, sold to Roche ($RHHBY) in a $450 million deal; bluebird bio ($BLUE), which pulled off a $116 million IPO last year; and BioVex, which Amgen ($AMGN) acquired for up to $1 billion. More (PDF)